Overview

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to determine time to progression of the combination therapy sorafenib plus doxorubicin against standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.

Phase:

Phase 2

Details

Lead Sponsor:

PD Dr. med. Matthias Dollinger

Treatments:

Doxorubicin
Liposomal doxorubicin
Niacinamide
Sorafenib